Benralizumab for Hypereosinophilic Syndrome

The monoclonal antibody against the interleukin-5 receptor was well tolerated and effective in reducing absolute eosinophil counts in symptomatic patients.

Although imatinib is highly effective in controlling eosinophilia and clinical manifestations in patients with hypereosinophilia and PDGFRA rearrangements, patients with hypereosinophilic syndrome (HES) lacking this molecular abnormality have limited treatment options. Benralizumab — a monoclonal antibody against the eosinophilopoietic cytokine interleukin-5 (IL5) receptor — depletes eosinophils and was shown to be effective in treating patients with eosinophilic asthma (Lancet 2016; 388:2128).

Based on the success of benralizumab in the setting of eosinophilic asthma, NIH investigators have conducted a randomized, double-blind, placebo-controlled, phase II trial to examine the agent's efficacy in patients with HES. A total of 20 patients wi…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Benralizumab for Hypereosinophilic Syndrome

Topics

Reviewing Author